Obesity and target organ damage: Diabetes

International Journal of Obesity

Volumn 26, Issue , 2002, Pages S11-S14

  Adler, A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Beta blockers; Diabetes; Diabetic complications; Insulin; Metformin; Obesity; Sulphonylureas; Weight gain

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; SULFONYLUREA DERIVATIVE;

BODY WEIGHT; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; WEIGHT GAIN;

ADULT; AGED; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; OBESITY; RISK FACTORS; WEIGHT GAIN; WEIGHT LOSS;

EID: 0036951028     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802212     Document Type: Article

References (16)

1. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581–1586.
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346: 393–403.
3. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaaniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001; 344: 1343–1350.
4. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20–25.
5. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the US: 1990–1998. Diabetes Care 2000; 23: 1278–1283.
6. National Audit Office. Tackling Obesity in England: Report by the Comptroller and Auditor General. The Stationery Office: London; 2001(available at www.nao.gov.uk).
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–713.
9. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713–720.
10. UK Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995; 310: 83–88.
11. Manley SE, Stratton IM, Cull CA, Frighi V, Eeley EA, Matthews DR, Holman RR, Turner RC, Neil HA; United Kindgom Prospective Diabetes Study Group. Effect of three months’ diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). Diabet Med 2000; 17: 518–523.
12. Wing RR, Marcus MD, Epstein LH, Salata R. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabet Care 1987; 10: 563–566.
13. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study: a 9-year update of a randomized controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med 1996; 124: 136–145.
14. Adler AL, Stevens RJ, Holman RR for the UKPDS Groups. Risk factors for incident albuminuria and renal dysfunction in UKPDS. Diabetologia 2000; 43: Suppl 1, A25.
15. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001; 60: 219–227.
16. Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH, the EURODIAB IDDM complications study group. Factors associated with plasma lipids and lipoproteins in type 1 diabetes mellitus: the EURODIAB IDDM complications study. Diabet Med 2001; 18: 786–796.